Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse

Opioid Abuse Clinical Trial

Official title:

A Phase II, Single-Center, Randomized, Double-Blind Assessment of the Abuse Liability of Acurox (Oxycodone HCl and Niacin) Tablets in Subjects With a History of Opioid Abuse

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00699010
• Other study ID #: AP-ADF-111
• Status: Completed
• Phase: Phase 2
• Start date: March 2008
• Est. completion date: August 2008

Study information

• Verified date: October 2008
• Source: Acura Pharmaceuticals Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the abuse liability of 4 times (8 tablets) the usual recommended dose of Acurox (oxycodone HCl 40 mg plus niacin 240 mg) versus oxycodone HCL 40 mg alone in subjects with a history of opioid abuse.

Description:

In the Treatment Phase, subjects randomly received oxycodone HCl 40 mg administered in combination with niacin 240 mg and oxycodone HCl 40 mg alone in crossover design. 15 subjects were randomized to receive oxycodone/niacin first followed by oxycodone with a 48 hour washout between doses. 15 subjects randomized to receive oxycodone before the oxycodone/naicin dose with a 48 hour washout between doses. The purpose of the Treatment Phase was to assess the abuse liability and abuse deterrence potential of 4 times the recommended 2-tablet dose of Acurox® Tablets 5/30 mg versus oxycodone HCl 40 mg alone (8 tablets per dose).

All 30 subjects received a single dose of each study treatment. Subjects were fasted prior to dosing on all dose days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: August 2008
• Est. primary completion date: August 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Subject is male or female between 18 and 55 years of age

• Subject meets DSM-IV Criteria for the Diagnosis of Opioid Substance Abuse and subject is unlikely to experience an idiosyncratic reaction or respiratory depression after ingesting 40 mg of oxycodone

• Body weight is not more than 20% above or below ideal body weight

• Subject agrees to abstain from any Rx or OTC drugs (except as authorized by the Investigator) or alcohol

• Subject is in generally good health

• Subject is reliable, willing, cooperative, able to communicate effectively, and has a minimum of a 6th grade reading level

• Subject has an acceptable score on the MMSE for cognitive impairment

• For women of child-bearing potential: woman is not pregnant and not nursing, and is practicing an acceptable method of birth control

Exclusion Criteria:

• Subject has a disease that may endanger the subject or the validity of the data

• Subject is currently physically dependent on opiates or alcohol

• Subject was exposed to any investigational drug within 30 days prior to the inpatient phase

• Subject has a history of hypersensitivity to any drug, or a known allergy to any component of the study drug formulation

• Subject has a positive urine drug screen for a non-opiate drug

• Subject has a predisposing condition that may place the subject at risk for receiving niacin or oxycodone, or confound the study analyses

• Subject ingested niacin at doses higher than SDI within 14 days prior to the inpatient phase

• Subject has an abnormal bleeding tendency

Related Conditions & MeSH terms

• Opioid Abuse
• Substance-Related Disorders

Intervention

Drug:
• Acurox 5/30mg taken first
followed by oxycodone 5mg with 48 hour washout
• Oxycodone 5mg taken first
followed by Acurox 5/30mg with 48 hour washout

Locations

Country	Name	City	State
United States	Johns Hopkins Medical Center	Baltimore	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
Acura Pharmaceuticals Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Drug Like/Dislike Effect at 30 Minutes Post Dose (E 30 Min)	"Do you dislike or like the drug effect you are feeling now?" This question was rated on a 1 to 29 point VAS scale that was anchored in the center with "neither like nor dislike" (14), on the left with "dislike an awful lot" (1), and on the right with "like an awful lot" (29).	Effects assessed at 0.5 hours after dosing.